Skip to content

Clinical study of esketamine continuous intravenous analgesia in patients with postherpetic neuralgia

Clinical study of esketamine continuous intravenous analgesia in patients with postherpetic neuralgia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096641
Enrollment
Unknown
Registered
2025-01-27
Start date
2025-01-27
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postherpetic neuralgia

Interventions

Esketamine group:Esketamine for intravenous controlled analgesia
Control group:Normal saline for intravenous controlled analgesia

Sponsors

Ningbo Medical Centre Lihuili Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The diagnosis of PHN was based on the Expert Consensus on the Diagnosis and Treatment of herpes zoster in China (2022); 2. Have a history of shingles, and the neuralgia lasts for more than 1 month after recovery; 3. Age >=18 years old; 4. Visual simulation score >=4 points; 5. Shingles on the neck, chest and waist; 6. Complete clinical data.

Exclusion criteria

Exclusion criteria: 1. Hepatic and renal insufficiency; 2. Abnormal coagulation function; 3. Fitted with cardiac pacemaker and spinal cord stimulator; 4. There are serious spinal deformity, disc herniation, etc. 5. Injection site infection; 6. Poor compliance.

Design outcomes

Primary

MeasureTime frame
NRS score;

Secondary

MeasureTime frame
Central sensitization score;Seurm BDNF;PSQI score;

Countries

China

Contacts

Public ContactYingying Lou

Ningbo Medical Centre Lihuili Hospital

605570569@qq.com+86 17857436857

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026